healthcare News
Ocugen slides 13% on gene therapy data that trails interim results
Phase 2 OCU410 trial for dry AMD shows 31% lesion reduction, below earlier 54% interim readout
LENZ shares slide on weak first commercial quarter results
VIZZ eye treatment generates $1.6M in debut quarter, missing analyst expectations
Compass Pathways falls after earnings miss, Phase 3 catalysts intact
$200M warrant exercises extend runway into 2028 as psilocybin therapy advances toward FDA submission
Sanara MedTech crosses $100M revenue milestone
Adjusted EBITDA surges 87% as wound care company reaffirms 2026 growth outlook despite elevated debt
Surrozen shares flat after $20 EPS miss masked by cash reserves
Q4 $183M loss driven by non-cash charges; biotech maintains $89M cash position as pipeline progresses
Valneva shares plunge 37% on Lyme vaccine trial miss
Phase 3 study fails primary endpoint despite 73% efficacy in secondary analysis, casting doubt on approval timeline
Apogee Therapeutics surges 19% on positive eczema drug trial data
Phase 2 APEX trial shows durable response with less frequent dosing, positioning drug for Phase 3 in second half of 2026
Insmed ARIKAYCE study meets all endpoints despite 5.6% stock decline
Phase 3b ENCORE trial shows statistically significant improvements in MAC lung disease patients, supporting label expansion to broader patient population